Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094107 · ClinicalTrials.gov registry record · Phase 2
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
A Phase 2 study of Melanoma and Skin Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 12
- Study locations
NCT00094107: Completed Phase 2 study of Melanoma and Skin Neoplasms, sponsored by Pfizer.
NCT00094107 is a Phase 2 study of Melanoma and Skin Neoplasms that has completed, run by Pfizer. The registered enrollment target is 32 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00094107, a Phase 2 study of Melanoma and Skin Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Primary Outcome
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target les
Conditions Studied
Interventions
- DRUG Axitinib [AG-013736]
Study Locations (12)
Pennsylvania
- Pfizer Investigational Site - Clairton
- Pfizer Investigational Site - Greensburg
- Pfizer Investigational Site - Johnstown
- Pfizer Investigational Site - Pittsburgh
- Pfizer Investigational Site - Pittsburgh
- Pfizer Investigational Site - Wexford
Massachusetts
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Boston
California
- Pfizer Investigational Site - Orange
Florida
- Pfizer Investigational Site - Miami Beach
Other
- Pfizer Investigational Site - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
What the finished NCT00094107 record still lists
NCT00094107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Axitinib [AG-013736] is the first listed.
NCT00094107 lists 12 locations in 5 states (Pennsylvania, Massachusetts, California).
Frequently Asked Questions
What is clinical trial NCT00094107 about?
NCT00094107 is a clinical study titled "Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma". This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for me...
What is the current status of trial NCT00094107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-12. Estimated completion is 2008-04.
What conditions does trial NCT00094107 study?
This clinical trial studies the following conditions: Melanoma, Skin Neoplasms.
What interventions are being tested in trial NCT00094107?
The interventions under investigation include: Axitinib [AG-013736] (DRUG).
Who is sponsoring clinical trial NCT00094107?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00094107 being conducted?
This trial has 12 study locations across California, Florida, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00094107's enrollment target sits among peer trials
32 193rd of 266 higher than 72 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia